Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.44 AUD
Change Today +0.01 / 2.33%
Volume 356.3K
VLA On Other Exchanges
As of 1:55 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

viralytics ltd (VLA) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/15/15 - A$0.54
52 Week Low
05/6/14 - A$0.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VIRALYTICS LTD (VLA)

Related News

No related news articles were found.

viralytics ltd (VLA) Related Businessweek News

No Related Businessweek News Found

viralytics ltd (VLA) Details

Viralytics Limited, a biotechnology company, develops oncolytic immunotherapy treatments for a range of cancers in Australia. It offers CAVATAK, a lead product that is in phase II clinical trial for the treatment of late stage melanoma, prostate, lung, and bladder cancer, as well as in phase ½ multi-dose intravenous clinical trial for late-stage melanoma, non-small cell lung, metastatic bladder, and castrate-resistant prostate cancer. The company is also conducting various preclinical studies on CAVATAK for the treatment of breast, multiple myeloma, pancreatic, and malignant glioma cancer, as well as for acute myeloid leukemia and chronic lymphocytic leukemia. In addition, it is developing EVATAK, which is in pre-clinical studies for treating ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

3 Employees
Last Reported Date: 08/26/14

viralytics ltd (VLA) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$429.0K
Chief Financial Officer
Total Annual Compensation: A$149.5K
Chief Scientific Officer
Total Annual Compensation: A$195.7K
Compensation as of Fiscal Year 2014.

viralytics ltd (VLA) Key Developments

Viralytics Limited Presents at 27th Annual ROTH Conference, Mar-09-2015 04:00 PM

Viralytics Limited Presents at 27th Annual ROTH Conference, Mar-09-2015 04:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.

Viralytics Limited Shows Positive CAVATAK Data at Cancer Conference

Viralytics Limited announced the presentation of further results demonstrating improved CAVATAK anti-cancer activity when used in combination with immune checkpoint inhibitors at the 29th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Maryland, USA. The presentation included data from a preclinical study assessing the activity of CAVATAK given in combination with mouse homologues of either the anti-CTLA-4 monoclonal antibody, Ipilimumab or the anti-PD-1 monoclonal antibody, Pembrolizumab - two checkpoint inhibitors that represent a new, highly promising class of cancer immunotherapies. In both cases, the combination of CAVATAK with the checkpoint inhibitor produced superior efficacy outcomes in a mouse melanoma study, compared with the efficacy of either agent alone. CAVATAK is a proprietary formulation of a common cold virus that has been shown to preferentially infect and attack cancer cells. The SITC meeting is a cancer immunotherapy conference with over 1,100 attendees, including scientists from academia, government and the pharmaceutical industry, along with other top medical professionals from around the world. Cancer immunotherapy treatments are forecast to become the single biggest class of therapeutics with the global market estimated at $35 billion by 2023.

Viralytics Limited Announces Change of Company Secretary

Viralytics Limited announced that Catherine Officer has resigned as company secretary and Sarah Prince has been appointed as company secretary, effective immediately. As Ms Prince and Ms Officer both work as solicitors for Company Matters Pty Limited this is a continuation of the existing engagement between VLA and Company Matters Pty Limited and ensures a seamless transition.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLA:AU A$0.44 AUD +0.01

VLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VLA.
View Industry Companies

Industry Analysis


Industry Average

Valuation VLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.0x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIRALYTICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at